ArticleThe Journal of biological chemistry2025
RhoE downregulation leads to enhanced cholesterol biosynthesis and sorafenib resistance in hepatocellular carcinoma.
Article in The Journal of biological chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sorafenib remains the first-line systemic therapy for hepatocellular carcinoma (HCC), but its clinical efficacy is limited by acquired resistance. Here, we identified a significant association between acquired resistance to sorafenib and activation of the FAK signaling pathway. In vitro experiments confirmed that sorafenib suppresses Rho-related GTP-binding protein RhoE (RhoE) expression via Raf/MEK/ERK inhibition, thereby relieving its inhibitory effect on the transforming protein RhoA (RhoA) and Rho-associated protein kinase signaling pathway and ultimately leading to elevated phosphorylation of FAK at tyrosine 397 in HCC cells. Activated FAK subsequently promotes 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) expression via AKT signaling, thereby increasing intracellular cholesterol levels, which in turn upregulates glioma-associated oncogene homolog 1 (GLI1) expression and induces drug resistance. Genetic knockout of FAK or pharmacological inhibition using defactinib or PF-573228 effectively suppressed the sorafenib-induced upregulation of AKT and HMGCR. Notably, combination treatment with FAK inhibitors and sorafenib synergistically inhibited HCC cell viability, an effect reversed by HMGCR overexpression or exogenous cholesterol. In vivo and organoid experiments further demonstrated that combining sorafenib with defactinib significantly suppressed tumor growth and resistance signaling. Furthermore, bioinformatic analyses revealed that a gene signature related to cholesterol biosynthesis is significantly associated with poor prognosis in sorafenib-treated HCC patients, indicating its potential as a predictive biomarker. Collectively, this study identify systematically uncovers a new mechanism of sorafenib resistance in HCC: RhoE downregulation-mediated activation of the FAK/AKT-cholesterol-SHH/GLI1 axis as a key driver of sorafenib resistance and provide a rationale for combining FAK inhibitors with RAF-targeted therapies and for using cholesterol biosynthesis signatures to guide personalized treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.